NASDAQ:AERIAerie Pharmaceuticals Stock Price, Forecast & News

Aerie Pharmaceuticals' stock was trading at $14.55 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AERI shares have decreased by 14.8% and is now trading at $12.40.
View which stocks have been most impacted by COVID-19.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aerie Pharmaceuticals.

Aerie Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Aerie Pharmaceuticals.

Aerie Pharmaceuticals Inc (NASDAQ:AERI) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.79) by $0.04. Aerie Pharmaceuticals had a negative return on equity of 107.42% and a negative net margin of 247.36%.
View Aerie Pharmaceuticals' earnings history.

13 equities research analysts have issued 12-month price objectives for Aerie Pharmaceuticals' stock. Their forecasts range from $17.00 to $50.00. On average, they anticipate Aerie Pharmaceuticals' share price to reach $30.08 in the next year. This suggests a possible upside of 142.6% from the stock's current price.
View analysts' price targets for Aerie Pharmaceuticals.

Media stories about AERI stock have trended positive recently, InfoTrie reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Aerie Pharmaceuticals earned a coverage optimism score of 2.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term.
View the latest news about Aerie Pharmaceuticals.

Aerie Pharmaceuticals saw a decline in short interest in July. As of July 31st, there was short interest totaling 8,050,000 shares, a decline of 10.6% from the July 15th total of 9,000,000 shares. Based on an average daily trading volume, of 879,200 shares, the days-to-cover ratio is presently 9.2 days. Currently, 18.4% of the company's stock are sold short.
View Aerie Pharmaceuticals' Short Interest.

Some companies that are related to Aerie Pharmaceuticals include Immunovant (IMVT), Legend Biotech (PCVX), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Mesoblast (MESO), Sangamo Therapeutics (SGMO), BAVARIAN NORDIC/S (BVNRY), Revolution Medicines (RVMD), Coherus Biosciences (CHRS), Forma Therapeutics (FMTX), NanoString Technologies (NSTG), Cortexyme (CRTX), Regenxbio (RGNX), Beam Therapeutics (BEAM) and Adverum Biotechnologies (ADVM).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Canopy Growth (CGC), NicOx (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), NVIDIA (NVDA), Puma Biotechnology (PBYI), Wells Fargo & Co (WFC), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD) and Incyte (INCY).

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Aerie Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include William Blair Investment Management LLC (2.95%), Bank of New York Mellon Corp (2.76%), Candriam Luxembourg S.C.A. (1.27%), Rhenman & Partners Asset Management AB (1.27%), Frontier Capital Management Co. LLC (1.09%) and Goldman Sachs Group Inc. (1.09%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino, Thomas A Mitro and Vicente Anido Jr.
View institutional ownership trends for Aerie Pharmaceuticals.

AERI stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, SG Americas Securities LLC, FMR LLC, Rhenman & Partners Asset Management AB, Candriam Luxembourg S.C.A., Bank of New York Mellon Corp, CWM LLC, and Spark Investment Management LLC.
View insider buying and selling activity for Aerie Pharmaceuticals.

AERI stock was purchased by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Goldman Sachs Group Inc., Granite Investment Partners LLC, Barclays PLC, Frontier Capital Management Co. LLC, AlphaCrest Capital Management LLC, Envestnet Asset Management Inc., and ProShare Advisors LLC. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino, and Vicente Anido Jr.
View insider buying and selling activity for Aerie Pharmaceuticals.

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AERI stock can currently be purchased for approximately $12.40.

Aerie Pharmaceuticals has a market capitalization of $576.77 million and generates $69.89 million in revenue each year. The company earns $-199,580,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Aerie Pharmaceuticals employs 353 workers across the globe.

The official website for Aerie Pharmaceuticals is www.aeriepharma.com.

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]